Agile Therapeutics, Inc. (NASDAQ:AGRX) Given Average Recommendation of “Hold” by Brokerages

Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) have been assigned an average rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $127.07.

A number of brokerages recently commented on AGRX. Maxim Group lowered Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, April 8th. Zacks Investment Research lowered Agile Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, April 4th. Finally, StockNews.com initiated coverage on Agile Therapeutics in a research report on Wednesday. They set a “sell” rating on the stock.

NASDAQ AGRX opened at $2.29 on Friday. The company has a fifty day moving average of $11.19 and a two-hundred day moving average of $18.40. The firm has a market capitalization of $7.72 million, a price-to-earnings ratio of -0.07 and a beta of 1.11. Agile Therapeutics has a 52 week low of $2.26 and a 52 week high of $76.80.

Agile Therapeutics (NASDAQ:AGRX – Get Rating) last released its quarterly earnings data on Wednesday, March 30th. The specialty pharmaceutical company reported ($8.00) earnings per share for the quarter, missing the consensus estimate of ($6.80) by ($1.20). The firm had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.58 million. Agile Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 376.29%. During the same quarter in the previous year, the firm earned ($8.00) earnings per share. As a group, research analysts anticipate that Agile Therapeutics will post -15.8 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. First Citizens Bank & Trust Co. acquired a new position in Agile Therapeutics during the first quarter worth approximately $42,000. Renaissance Technologies LLC boosted its stake in shares of Agile Therapeutics by 341.6% in the fourth quarter. Renaissance Technologies LLC now owns 162,900 shares of the specialty pharmaceutical company’s stock valued at $80,000 after buying an additional 126,015 shares in the last quarter. Virtu Financial LLC boosted its stake in shares of Agile Therapeutics by 771.4% in the fourth quarter. Virtu Financial LLC now owns 237,642 shares of the specialty pharmaceutical company’s stock valued at $116,000 after buying an additional 210,370 shares in the last quarter. Summit Global Investments purchased a new stake in shares of Agile Therapeutics in the third quarter valued at approximately $121,000. Finally, GSA Capital Partners LLP boosted its position in Agile Therapeutics by 25.1% during the fourth quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company’s stock worth $358,000 after purchasing an additional 147,194 shares in the last quarter. 25.87% of the stock is currently owned by institutional investors and hedge funds.

About Agile Therapeutics (Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading